Isomorphic Labs, a young company whose artificial intelligence technology for drug research has already landed partnerships with big pharmaceutical companies, unveiled $600 million in new financing this week as it looks to advance its own drug pipeline.
London-based Isomorphic is an autonomous subsidiary of Alphabet. It came from DeepMind, a different Alphabet subsidiary that uses machine learning to solve problems. Isomorphic was formed in 2021 to build on the success of…
Article Source
https://medcitynews.com/2025/04/an-ai-biotech-hauls-in-600m-plus-more-funding-highlights-to-close-1q-2025/
